Opportunity Information: Apply for RFA HL 12 009
Apply for RFA HL 12 009
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Anchoring Metabolomic Changes to Phenotype (P20)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research.
- This funding opportunity was created on Apr 5, 2011 and posted on Apr 5, 2011.
- Applicants must submit their applications by Jun 17, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $26,000,000.00 to eligible and selected applicants.
- Eligible applicants include: County governments Public and State controlled institutions of higher education Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) State governments For profit organizations other than small businesses Private institutions of higher education Small businesses Native American tribal governments (Federally recognized) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non U.S.) components of U.S. Organizations are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Anchoring Metabolomic Changes to Phenotype (P20) (RFA-HL-12-009) was a discretionary NIH grant opportunity issued by the National Heart, Lung, and Blood Institute (NHLBI) to support early-stage, program-style efforts that connect metabolomic measurements to real-world cardiovascular and lung disease phenotypes. The main goal was to use metabolomic profiling in already-established human cohorts to move beyond simple biomarker discovery and toward a clearer mechanistic understanding of what molecular pathways and determinants are driving differences in disease susceptibility, clinical presentation, and outcomes. In practical terms, the FOA sought projects that could leverage existing cohort resources (for example, stored biospecimens and well-characterized clinical data) to identify metabolite patterns linked to heart and lung disease traits, then use those findings to improve prediction of disease risk, support diagnosis and risk stratification, and inform how patients respond to therapies and what their prognosis might be.
A defining feature of the announcement was its emphasis on an integrated, multidisciplinary program built around two tightly connected components: a metabolomic component and a mechanistic component. The metabolomic component focused on generating and analyzing metabolomic phenotyping data in existing cohorts, using appropriate platforms and rigorous analytical approaches to relate metabolite signatures to specific disease phenotypes. The mechanistic component was intended to follow up on those metabolomic signals to test biological plausibility and causal pathways, helping to explain how and why particular metabolite changes relate to disease processes. Importantly, the FOA described these components as iterative and mutually informative: cohort-based metabolomic results were expected to guide mechanistic hypotheses, while mechanistic insights were expected to refine cohort analyses, target additional measurements, and strengthen interpretation of observed metabolite-phenotype associations.
The opportunity used the NIH P20 activity code, which is typically aimed at exploratory, developmental, and planning-style center or program initiatives that build a foundation for larger efforts. The funding instrument was a grant, with no cost sharing or matching required. The opportunity was posted on April 5, 2011, with an original and current closing date of June 17, 2011, and it was later archived on July 18, 2011. NHLBI estimated total funding at approximately $26,000,000 across awarded projects, signaling an intention to support multiple teams and encourage broad participation in metabolomics-driven cardiovascular and pulmonary research.
Eligibility was broad and included many types of domestic U.S. entities: state, county, city or township governments; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; public housing authorities/Indian housing authorities; special district governments; independent school districts; small businesses and for-profit organizations other than small businesses; and federally recognized tribal governments as well as other tribal organizations. The FOA explicitly extended eligibility to a range of institution types often highlighted in NIH opportunities, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, and eligible federal agencies. Non-U.S. entities (foreign organizations) were not eligible to apply, and foreign components of U.S. organizations were not allowed, reinforcing that the supported research infrastructure and performance were expected to be U.S.-based.
Programmatically, the FOA sat within NIH’s broader cardiovascular and pulmonary research missions, aligning with CFDA numbers 93.837 (Cardiovascular Diseases Research) and 93.838 (Lung Diseases Research). At its core, it encouraged teams that could bring together expertise in cohort epidemiology, clinical phenotyping, metabolomics technologies, biostatistics/bioinformatics, and experimental or translational biology. The intended outcome was not only to catalog metabolite associations, but to anchor those metabolomic changes to specific phenotypes with credible mechanistic explanations that could eventually translate into better tools for assessing risk, diagnosing disease, tailoring treatment, and predicting outcomes in heart and lung conditions.
Frequently Asked Questions (FAQs)
What is the "Anchoring Metabolomic Changes to Phenotype (P20)" opportunity?
It was a discretionary NIH funding opportunity (RFA-HL-12-009) issued by the National Heart, Lung, and Blood Institute (NHLBI) to support early-stage, program-style efforts that connect metabolomic measurements to real-world cardiovascular and lung disease phenotypes.
Which NIH institute issued this funding opportunity?
The opportunity was issued by the National Heart, Lung, and Blood Institute (NHLBI), a component of NIH.
What does the activity code P20 mean in this context?
The opportunity used the NIH P20 activity code, which is typically aimed at exploratory, developmental, and planning-style center or program initiatives intended to build a foundation for larger efforts.
What kind of projects was this FOA trying to support?
The FOA sought integrated, multidisciplinary programs that use metabolomic profiling in already-established human cohorts to move beyond simple biomarker discovery and toward clearer mechanistic understanding of molecular pathways and determinants driving differences in disease susceptibility, clinical presentation, and outcomes in heart and lung disease.
What was the main scientific goal?
The main goal was to connect metabolomic changes to specific cardiovascular and pulmonary phenotypes and anchor those associations with credible mechanistic explanations, so the findings could better inform risk prediction, diagnosis and risk stratification, therapy response, and prognosis.
Was the focus limited to biomarker discovery?
No. The FOA explicitly emphasized moving beyond simple biomarker discovery toward mechanistic understanding of what pathways and determinants drive observed metabolite-phenotype relationships.
What populations or study designs did the FOA emphasize?
It emphasized using metabolomic profiling in already-established human cohorts, particularly where investigators could leverage existing cohort resources such as stored biospecimens and well-characterized clinical data.
What are the two required or emphasized components of the program?
A defining feature was an integrated program built around two tightly connected components: (1) a metabolomic component and (2) a mechanistic component.
What was expected in the metabolomic component?
The metabolomic component focused on generating and analyzing metabolomic phenotyping data in existing cohorts, using appropriate platforms and rigorous analytical approaches to relate metabolite signatures to specific heart and lung disease phenotypes.
What was expected in the mechanistic component?
The mechanistic component was intended to follow up on metabolomic signals to test biological plausibility and causal pathways, helping explain how and why particular metabolite changes relate to disease processes.
How were the metabolomic and mechanistic components supposed to work together?
The FOA described the components as iterative and mutually informative: cohort-based metabolomic results were expected to guide mechanistic hypotheses, while mechanistic insights were expected to refine cohort analyses, target additional measurements, and strengthen interpretation of metabolite-phenotype associations.
What kinds of outcomes or impacts did NHLBI want from funded programs?
The intended outcomes included identifying metabolite patterns linked to cardiovascular and pulmonary traits and using those results to improve prediction of disease risk, support diagnosis and risk stratification, and inform how patients respond to therapies and what prognosis might be.
Did the FOA specify particular diseases?
The description focuses on cardiovascular and lung disease phenotypes broadly, aligned with NHLBI mission areas, rather than naming specific individual conditions.
What funding instrument was used?
The funding instrument was a grant.
Was cost sharing or matching required?
No. The opportunity stated there was no cost sharing or matching required.
How much total funding was NHLBI estimating for this opportunity?
NHLBI estimated total funding at approximately $26,000,000 across awarded projects, indicating an intention to support multiple teams.
When was the opportunity posted?
It was posted on April 5, 2011.
What were the closing date(s) for applications?
The original and current closing date listed was June 17, 2011.
Is this opportunity still open?
No. The announcement was later archived on July 18, 2011.
Who was eligible to apply?
Eligibility was broad and included many types of domestic U.S. entities such as state/county/city or township governments; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; public housing authorities/Indian housing authorities; special district governments; independent school districts; small businesses; for-profit organizations other than small businesses; federally recognized tribal governments; and other tribal organizations. The FOA also highlighted eligibility for institution types often noted in NIH opportunities, including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, and eligible federal agencies.
Were foreign organizations eligible to apply?
No. Non-U.S. entities (foreign organizations) were not eligible to apply.Were foreign components of U.S. organizations allowed?
No. Foreign components of U.S. organizations were not allowed, indicating the supported research infrastructure and performance were expected to be U.S.-based.
What research areas did this FOA align with?
It aligned with NIH cardiovascular and pulmonary research missions and referenced CFDA numbers 93.837 (Cardiovascular Diseases Research) and 93.838 (Lung Diseases Research).
What kinds of expertise did the FOA encourage teams to bring together?
The FOA encouraged multidisciplinary teams with expertise spanning cohort epidemiology, clinical phenotyping, metabolomics technologies, biostatistics/bioinformatics, and experimental or translational biology.
What types of cohort resources were specifically mentioned as valuable?
The FOA mentioned leveraging existing cohort resources such as stored biospecimens and well-characterized clinical data.
What types of analyses were expected for metabolite-phenotype relationships?
The metabolomic component was expected to use rigorous analytical approaches to relate metabolite signatures to specific disease phenotypes, with the understanding that mechanistic insights would help refine and strengthen interpretation.
What was meant by "anchoring" metabolomic changes to phenotype?
Based on the FOA description, it meant linking metabolomic patterns observed in cohort samples to specific cardiovascular or lung disease traits and then supporting those links with mechanistic follow-up that tests plausibility and causal pathways, rather than stopping at association findings.
Browse more opportunities from the same category: Health
Next opportunity: Basic Research in Calcific Aortic Valve Disease (R01)
Previous opportunity: REQUEST FOR COMMENTS South Africa Comprehensive Clinical HIV Related Service, Support and Capacity Development, in line with South African national, provincial and district policies, standards and implementation plans
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 009
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic Research in Calcific Aortic Valve Disease (R01) Apply for RFA HL 12 015 Funding Number: RFA HL 12 015 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pulmonary Vascular Right Ventricular Axis Research Program (R01) Apply for RFA HL 12 021 Funding Number: RFA HL 12 021 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Short Term Institutional Training Grant for Clinician Scientists in Pediatric Respiratory, Sleep and Hematology/Transfusion Medicine (T35) Apply for RFA HL 12 017 Funding Number: RFA HL 12 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pathophysiology of HIV Associated Neurodegeneration in Aging Populations on Long Term Anti Retroviral Therapy (R01) Apply for RFA MH 12 070 Funding Number: RFA MH 12 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pathophysiology of HIV Associated Neurodegeneration in Aging Populations on Long Term Anti Retroviral Therapy (R21) Apply for RFA MH 12 071 Funding Number: RFA MH 12 071 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| 2011 Announcement of Availability of Funds for One Cooperative Agreement to Publish Public Health Reports Apply for SG PHR 11 001 Funding Number: SG PHR 11 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: Case Dependent |
| Planning Grants for Expansion of the Comprehensive Community Mental Health Services for Children and their Families Apply for SM 11 008 Funding Number: SM 11 008 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $800,000 |
| Allergen Epitope Research and Validation Cnters (U19) Apply for RFA AI 11 013 Funding Number: RFA AI 11 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition The Health and Retirement Study (U01) Apply for RFA AG 12 001 Funding Number: RFA AG 12 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Health Fellows Program II (GHFP II) Apply for SOL OAA 11 000042 Funding Number: SOL OAA 11 000042 Agency: Agency for International Development Category: Health Funding Amount: $220,000,000 |
| Improving Child and Maternal Nutrition in Tanzania Apply for USAID TANZAIA 11 005 RFA Funding Number: USAID TANZAIA 11 005 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $35,000,000 |
| Life After Linkage The Future of Family Studies (R01) Apply for RFA HL 12 007 Funding Number: RFA HL 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Understanding Clinical Information Needs and Health Care Decision Making Processes in the Context of Health Information Technology (IT) (R01) Apply for PA 11 198 Funding Number: PA 11 198 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Academic Career Award (Parent K07) Apply for PA 11 192 Funding Number: PA 11 192 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders Apply for CDC RFA DD11 1103 Funding Number: CDC RFA DD11 1103 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Understanding User Needs and Context to Inform Consumer Health Information Technology (IT) Design (R01) Apply for PA 11 199 Funding Number: PA 11 199 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Services Grant Program for Residential Treatment for Pregnant and Postpartum Women Apply for TI 11 009 Funding Number: TI 11 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $524,000 |
| Grants to Enhance Older Adult Behavioral Health Services Apply for SM 11 009 Funding Number: SM 11 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $356,344 |
| Cooperative Agreement for the Drug Demand Reduction Initiative for Iraq Apply for TI 11 011 Funding Number: TI 11 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $770,000 |
| Service Area Competition Additional Areas Apply for HRSA 11 178 Funding Number: HRSA 11 178 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,072,582 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.